Results 41 to 50 of about 5,863 (219)

The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease [PDF]

, 2018
Influenza A virus (IAV) causes a disease burden in the swine industry in the US and is a challenge to prevent due to substantial genetic and antigenic diversity of IAV that circulate in pig populations.
Gauger, P C, Lewis, N S, Lopes, S, Loving, C L, Rajão, D S, Sandbulte, M R, Souza, C K, Vincent, A L   +7 more
core   +2 more sources

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy [PDF]

American Journal of Epidemiology, 2013
MF59-adjuvanted trivalent influenza vaccine (Novartis Vaccines and Diagnostics, Siena, Italy) has been shown to be more effective than nonadjuvanted vaccine in the elderly population. Here we present results from a large-scale, observational, noninterventional, prospective postlicensure study that evaluated the safety of MF59-adjuvanted vaccine in ...
VILLA, MARCO, S. Black, N. Groth, K. J. Rothman, G. Apolone, N. S. Weiss, I. Aquino, L. Boldori, F. Caramaschi, A. Gattinoni, G. Malchiodi, A. Crucitti, G. Della Cioppa, E. Scarpini, D. Mavilio, S. Mannino   +15 more
openaire   +3 more sources

New cutaneous vaccine adjuvant that STINGs a little less [PDF]

, 2016
Cutaneous vaccination can be a challenge because the development of local skin inflammation is often unavoidable. Thus, it is important to identify and validate new vaccine adjuvants that enhance immunization without the burden of inflammation.
Caucheteux, Stephane, Piguet, Vincent
core   +1 more source

MF59 adjuvant: the best insurance against influenza strain diversity

Expert Review of Vaccines, 2011
MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad®), Novartis, Cambridge, MA, USA). Recently, MF59 was shown to be safe in a seasonal influenza vaccine for young children and was able to increase vaccine efficacy from 43 to 89%. A
Derek T, O'Hagan, Rino, Rappuoli, Ennio, De Gregorio, Theodore, Tsai, Giuseppe, Del Giudice   +4 more
openaire   +2 more sources

Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders

Human Vaccines & Immunotherapeutics, 2019
Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose.
Christine Robinson, Carly Baehr, Shirdi E. Schmiel, Claudia Accetturo, Daniel L. Mueller, Marco Pravetoni   +5 more
doaj   +1 more source

Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults

Vaccine, 2020
Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a noninferior immune response compared with a licensed adjuvanted trivalent influenza vaccine (aTIV-1; Fluad™) and aTIV-2 containing an alternate B strain, examine whether aQIV had immunological superiority for the B strain absent from aTIV comparators, and evaluate ...
Brandon, Essink, Carlos, Fierro, Jeffrey, Rosen, Amparo L, Figueroa, Bin, Zhang, Carole, Verhoeven, Jonathan, Edelman, Igor, Smolenov   +7 more
openaire   +2 more sources

Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination [PDF]

Journal of Clinical Investigation, 2019
Seasonal and pandemic influenza infection remains a major public health concern worldwide. Driving robust humoral immunity has been a challenge given preexisting, often cross-reactive, immunity and in particular, poorly immunogenic avian antigens. To overcome immune barriers, the adjuvant MF59 has been used in seasonal influenza vaccines to increase ...
Carolyn M. Boudreau, Wen-Han Yu, Todd J. Suscovich, H. Keipp Talbot, Kathryn M. Edwards, Galit Alter   +5 more
openaire   +2 more sources

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

Viruses, 2022
The global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become more serious because of the continuous emergence of variants of concern (VOC), thus calling for the development ...
Naru Zhang, Qianting Ji, Zezhong Liu, Kaiming Tang, Yubin Xie, Kangchen Li, Jie Zhou, Sisi Li, Haotian Shang, Zecan Shi, Tianyu Zheng, Jiawei Yao, Lu Lu, Shuofeng Yuan, Shibo Jiang   +14 more
doaj   +1 more source

Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. [PDF]

, 2016
INTRODUCTION: The influenza vaccine is less immunogenic in older than younger adults, and the duration of protection is unclear. Determining if protection persists beyond a typical seasonal epidemic is important for climates where influenza virus ...
Cook, Alex R, I-Cheng, Mark Chen, Parry, Christopher M, Wilder-Smith, Annelies, Young, Barnaby, Zhao, Xiahong   +5 more
core   +1 more source

The post-2009 influenza pandemic era : time to revisit antibody immunodominance [PDF]

, 2018
The current inactivated influenza vaccines rely on the induction of neutralizing antibodies against the head domain of the viral hemagglutinin (HA). The HA head contains five immunodominant antigenic sites, all of which are subject to antigenic drift ...
Caton, Khurana, Krammer, Krause, Kristien Van Reeth, Liu, Van Reeth   +6 more
core   +1 more source